Molbio Diagnostics IPO Day 3 Subscription Status: Issue Booked 5.28x So Far
Authored By HDFC SKY | Published at: Aug 12, 2026 11:48 AM IST
Molbio Diagnostics IPO was subscribed 5.28 times by 10:54 AM on Day 3, with NII/HNI demand at 11.53 times and retail subscription at 4.81 times.
Mumbai, August 12: Molbio Diagnostics IPO saw strong demand on the third and final day of bidding, with the ₹939.70 crore issue subscribed 5.28 times by 10:54 AM on August 12, 2026.
The issue opened for subscription on August 10 and closes today, August 12. Investors had placed bids for 4,30,48,692 shares against 81,58,529 shares offered for public subscription, according to the latest subscription data.
Demand remained particularly firm among non-institutional investors. The NII/HNI category was subscribed 11.53 times, while retail investors had subscribed 4.81 times. The QIB portion, excluding anchor investors, stood at 1.40 times.
The employee category was subscribed 6.05 times.
Molbio Diagnostics IPO Day 3 Subscription Status
As of 10:54:48 AM on August 12, the Molbio Diagnostics IPO had received 9,68,917 applications. The overall issue was subscribed 5.28 times, with bids exceeding the available public quota by a sizeable margin.
| Category | Shares Offered | Shares Bid For | Subscription |
| QIB (Ex Anchor) | 23,25,146 | 32,65,110 | 1.40x |
| NII/HNI | 17,43,859 | 2,01,03,822 | 11.53x |
| Retail | 40,69,004 | 1,95,55,668 | 4.81x |
| Employees | 20,520 | 1,24,092 | 6.05x |
| Total | 81,58,529 | 4,30,48,692 | 5.28x |
The NII/HNI segment was the strongest among the main investor categories. Within it, the sNII portion was subscribed 13.75 times, while the bNII category recorded 10.42 times subscription.
Category-wise Molbio Diagnostics IPO Subscription Status
The QIB portion moved to 1.40 times by the latest update, compared with 1.39 times at the end of Day 2. Retail subscription also climbed from 3.19 times on Day 2 to 4.81 times.
| Category | Shares Offered | Shares Bid For | Subscription |
| QIB (Ex Anchor) | 23,25,146 | 32,65,110 | 1.40x |
| NII/HNI | 17,43,859 | 2,01,03,822 | 11.53x |
| bNII (> ₹10 lakh) | 11,62,573 | 1,21,08,672 | 10.42x |
| sNII (< ₹10 lakh) | 5,81,286 | 79,95,150 | 13.75x |
| Retail | 40,69,004 | 1,95,55,668 | 4.81x |
| Employees | 20,520 | 1,24,092 | 6.05x |
| Total | 81,58,529 | 4,30,48,692 | 5.28x |
Molbio Diagnostics Day-Wise Subscription Summary
Subscription strengthened sharply after the first day. The IPO moved from 0.83 times at the end of Day 1 to 2.95 times on Day 2, before reaching 5.28 times by the Day 3 morning update.
| Date | QIB (Ex Anchor) | NII/HNI | Retail | Employees | Total |
| August 10, 2026 (Day 1) | 1.00x | 0.73x | 0.77x | 2.12x | 0.83x |
| August 11, 2026 (Day 2) | 1.39x | 4.46x | 3.19x | 4.79x | 2.95x |
| August 12, 2026 (Day 3, 10:54 AM) | 1.40x | 11.53x | 4.81x | 6.05x | 5.28x |
The latest figures are based on bids recorded up to 10:54:48 AM on August 12. The issue is scheduled to close later today.
Molbio Diagnostics IPO Timeline
| IPO Milestone | Date |
| Issue Open Date | August 10, 2026 |
| Issue Close Date | August 12, 2026 |
| Basis of Allotment Date | August 13, 2026 |
| Initiation of Refunds | August 14, 2026 |
| Credit of Shares | August 14, 2026 |
| Listing Date | August 17, 2026 |
Brief Overview Of The Molbio Diagnostics IPO
Molbio Diagnostics IPO is a ₹939.70 crore book-built issue comprising a fresh issue of 24,80,246 shares aggregating up to ₹200 crore and an offer for sale of 91,66,000 shares aggregating up to ₹739.70 crore.
The IPO price band is ₹768 to ₹807 per share. The minimum application size for retail investors is 18 shares, requiring ₹14,526 at the upper end of the price band.
| IPO Detail | Particulars |
| Issue Size | ₹939.70 crore |
| Issue Type | Bookbuilding IPO |
| Fresh Issue | 24,80,246 shares |
| Offer for Sale | 91,66,000 shares |
| Price Band | ₹768 to ₹807 per share |
| Face Value | ₹1 per share |
| Lot Size | 18 shares |
| Minimum Retail Investment | ₹14,526 |
| QIB Reservation | 50.00% of net offer |
| NII/HNI Reservation | 15.00% of net offer |
| Retail Reservation | 35.00% of net offer |
| Employee Reservation | 20,520 shares |
| Employee Discount | ₹76 per share |
| Listing Exchanges | BSE and NSE |
| Tentative Listing Date | August 17, 2026 |
Molbio Diagnostics operates in the diagnostics and medical technology segment. The company is known for developing and manufacturing molecular diagnostic products and testing platforms.
The issue comprises both primary and secondary components. The fresh issue is expected to raise up to ₹200 crore, while the offer for sale accounts for up to ₹739.70 crore at the upper end of the price band.
The public offer, excluding the anchor portion and employee reservation, has been divided among QIB, NII/HNI and retail investors.
| Investor Category | Shares Reserved | % of Net Offer | % of Total Issue |
| QIB | 58,12,863 | 50.00% | 49.91% |
| NII/HNI | 17,43,859 | 15.00% | 14.97% |
| Retail | 40,69,004 | 35.00% | 34.94% |
| Employees | 20,520 | Preferential reservation | 0.18% |
| Total Issue | 1,16,46,246 | 100.00% | 100.00% |
At the upper end of the price band, Molbio Diagnostics has a market capitalisation of approximately ₹9,299.87 crore. The IPO closes on August 12, with the basis of allotment scheduled for August 13 and the shares expected to list on August 17, 2026.
Source:
- https://www.chittorgarh.net/reports/anchor-investor/molbio-ipo-anchor.pdf
Disclaimer
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please Note: The information shared is intended solely for informational purposes and does not make any investment recommendations
Join Us
Add as preferred source on Google
